Mereo BioPharma Group PLC expected to post a loss of 1 penny a share - Earnings Preview

Mereo BioPharma

09/05/2025 17:17

Mereo BioPharma Group PLC MREO.OQ, MREO.O is expected to show a rise in quarterly revenue when it reports  results on May 12 (estimated) for the period ending March 31 2025

The London United Kingdom-based   company is expected to report revenue of £14.505 million, according to the mean estimate from 6 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Mereo BioPharma Group PLC is for a loss of 1 penny per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Mereo BioPharma Group PLC is $7.00​, above​ its last closing price of $2.42. ​​​

Previous quarterly performance (using preferred earnings measure in pounds). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.01
-0.01
-0.04
Missed
-229.5
Sep. 30 2024
-0.02
-0.01
-0.08
Missed
-460.6
Jun. 30 2024
-0.01
-0.01
-0.08
Missed
-906.4​
0.00
​​Dec. 31 2023
0.00
​
Jun. 30 2023
0.00


This summary was machine generated May 9 at 16:17 GMT.  All figures in pounds unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)